Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com

StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a research note published on Saturday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners assumed coverage on Lipocine in a research note on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price target for the company.

Lipocine Price Performance

LPCN opened at $4.54 on Friday. The company’s 50 day moving average price is $5.08 and its two-hundred day moving average price is $5.62. The firm has a market capitalization of $24.28 million, a price-to-earnings ratio of -5.97 and a beta of 1.18. Lipocine has a fifty-two week low of $2.38 and a fifty-two week high of $11.79.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. As a group, equities research analysts predict that Lipocine will post -0.78 EPS for the current year.

Hedge Funds Weigh In On Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP purchased a new position in shares of Lipocine Inc. (NASDAQ:LPCN) in the second quarter, according to its most recent filing with the SEC. The firm purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine at the end of the most recent quarter. 9.11% of the stock is owned by institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.